CEREBROPROTEIN HYDROLYSATE INDUCED SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS): A CASE REPORT
DOI:
https://doi.org/10.22159/ijpps.2017v9i1.15138Keywords:
Cerebroprotein hydrolysate, Dementia, ischaemic stroke, Systemic inflammatory response syndromeAbstract
Cerebroprotein hydrolysate is a newer pharmacological neurotropic agent and considered as a promising therapeutic agent for dementia, Alzheimer's disease, traumatic brain injury and acute ischaemic stroke. Studies revealed that most of the side effects are minor. Here, we reported a case of Systemic inflammatory response syndrome (SIRS) probably due to use of Cerebroprotein hydrolysate in a patient with acute ischaemic stroke.
Downloads
References
Bae CY, Cho CY, Chok, Hoon oh B, Choi KG, Lee HS, et al. A double-blind placebo-controlled, multicenter study of cerebrolysin in Alzheimer’s disease. J Am Geriatr Soc 2000;48:1566–71.
M Phirke, A Bharati, AV Sausa, N Shah, S Sonavane. Cerebroprotein hydrolysate in the treatment of vascular dementia a case report. Int J Pharmacol Clin Sci 2014;3:75-8.
Karia S, Mahajan PT, De Sousa A. Cerebroprotein hydrolysate in traumatic brain injury. El Mednifico J 2014;2:34-5.
Karia S, Majlikar R, De Sousa A, Shah N. Cerebroprotein hydrolysate in the extra pontine myelinosis-a case report. Int J Sci Res Publication 2014;4:1-2.
Jain N, Yadav S, Gayal M, Singal KK, Gupta P, Bansal M. Cerebroprotein hydrolysate: Inoovation in neurodegenerative disorders. Int J Med Dental Sci 2014;3:132-3.
Arun Oommen. Cerebroprotein hydrolysate-new paradigm in the management of neurological problems. J Neurol Stroke 2015;2:76.
Praveen Gupta, Shailesh Yadav. Cerebroprotein hydrolysate: Innovation in the treatment of neurodegenerative disorders. J Indian Acad Clin Med 2014;15:132-3.
Guo Wei Yan, He Zong-Fang, WU Xin An, Chen Jun, Mao xiao, Guan Li, et al. Evidence-based analysis of a case with aggravating allergies after using multiple drugs in sequence. Pharm Care Res 2015;15:334-8.
The use of the WHO-UMC system for standardized case causality assessment. Uppsala: The Uppsala monitoring centre; 2005. Available from: http://www.who-umc.org/graphics/ 24734.pdf. [Last accessed on 05 Aug 2016]
Naranjo CA, Busto U, Seller EM, Sandor P, Ruiz I, Roberts EA. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-49.
Published
How to Cite
Issue
Section
